CLAIMS

1. A fusion protein comprising, from N-terminus to C-terminus:
    a) N-terminal secretion signal sequence of a secreted or a first membrane-bound protein;
    b) an antigen from a non-enveloped virus;
    c) a transmembrane domain of a second membrane-bound protein.

2. The fusion protein of claim 1, wherein said first protein is selected from the group consisting of Intereferon a, Interferon b, Interferon c, Interferon d, Interferon gamma, interleukine-2, interleukine 4, interleukine-12 Hemagglutinin (HE) protein of Infectious salmon anemia virus (ISAV), viral hemorrhagic septicemia virus G-protein and the fusion protein of Atlantic Salmon Paramyxovirus, and said second protein is independently selected from the group consisting of Hemagglutinin (HE) protein of Infectious salmon anemia virus (ISAV), viral hemorrhagic septicemia virus G-protein and the fusion protein of Atlantic Salmon Paramyxovirus

3. The fusion protein of claim 1 wherein the first membrane-bound protein is identical to the second membrane-bound protein.

4. The fusion protein of claim 3, wherein said membrane bound protein is viral hemorrhagic septicemia virus G-protein (VHSV-G).

5. The fusion protein of claim 4, wherein said N-terminal secretion signal sequence is at least 90% identical to SEQ ID NO: 7 or 48, or wherein said secretion signal sequence comprises a portion of SEQ ID NO: 48 or a sequence at least 90% identical to SEQ ID NO: 48, wherein said portion comprises SEQ ID NO: 7 or a sequence that is at least 90% identical to SEQ ID NO: 7.

6. The fusion protein of claim 5 wherein at least half of differing amino acids in said N-terminal secretion signal are conservative substitutions.

7. The fusion protein of any one of claims 1-6, wherein said transmembrane domain is at least 90% identical to SEQ ID NO: 8 or 49, or wherein said transmembrane fragment comprises a portion of SEQ ID NO: 49 or a sequence at least 90% identical to SEQ ID NO: 49, wherein said portion comprises SEQ ID NO: 8 or a sequence that is at least 90% identical to SEQ ID NO: 8.
8. The fusion protein of claim 7 wherein at least half of differing amino acids in said Transmembrane domain are conservative substitutions.
9. The fusion protein of any one of claims 1-8, wherein the non-enveloped virus is selected from the group consisting of Priscine Orthoreovirus (PRV), Piscine Myocarditis Syndrome Virus (PMCV), Infectious Pancreatic Necrosis Virus (IPNV), and betanodavirus.
10. The fusion protein of claim 9, wherein the antigen is PMCV ORF-1 antigen.
11. A nucleic acid sequence that encodes the fusion protein of any one of claims according to any one of claims 1-10.
12. The nucleic acid sequence according to claim 11, comprising SEQ ID NO: 16.
13. A vector comprising the nucleic acid sequence according to claim 11 and, optionally, further comprising a nucleic acid sequence encoding SEQ ID NO: 6 or 50, wherein said nucleic acid sequence encoding SEQ ID NO: 6 or 50 is SEQ ID NO: 17 or 20.
14. The vector of claim 13 which is a plasmid vector.
15. A host cell comprising the vector of claim 14.
16. A vaccine comprising the vector of claim 13 or claim 14.
17. The vaccine according to claim 16 wherein the antigen is PMCV ORF-1 antigen.
18. A vaccine according to claim 16 for use in a method of protecting a salmonid against infection.

19. The vaccine of claim 16, wherein said salmonid is Atlantic salmon (*Salmo salar*), rainbow trout (*Oncorhynchus mykiss*), or Coho Salmon (*Oncorhynchus kisutch*).